New Developments in the Hormonal Treatment of Endometrial and Ovarian Cancer

Author(s):  
Günter Emons ◽  
Klaus-Dieter Schulz
2018 ◽  
Vol 78 (10) ◽  
pp. 972-976 ◽  
Author(s):  
Enzo Ricciardi ◽  
Thaïs Baert ◽  
Beyhan Ataseven ◽  
Florian Heitz ◽  
Sonia Prader ◽  
...  

AbstractIn the early 2000s a two-tier grading system was introduced for serous ovarian cancer. Since then, we have increasingly come to accept that low-grade serous ovarian carcinoma (LGSOC) is a separate entity with a unique mutational landscape and clinical behaviour. As less than 10% of serous carcinomas of the ovary are low-grade, they are present in only a small number of patients in clinical trials for ovarian cancer. Therefore the current treatment of LGSOC is based on smaller trials, retrospective series, and subgroup analysis of large clinical trials on ovarian cancer. Surgery plays a major role in the treatment of patients with LGSOC. In the systemic treatment of LGSOC, hormonal treatment and targeted therapies seem to play an important role.


1987 ◽  
Vol 23 (7) ◽  
pp. 915-916 ◽  
Author(s):  
Anders Jakobsen ◽  
Kamma Bertelsen ◽  
Arne Sell

2021 ◽  
Vol 12 (1) ◽  
pp. 38-53
Author(s):  
Vinaya Gogineni ◽  
Susan Morand ◽  
Hannah Staats ◽  
Rachel Royfman ◽  
Monika Devanaboyina ◽  
...  

2018 ◽  
Vol 25 ◽  
pp. 41-44 ◽  
Author(s):  
Chanhee Han ◽  
Stefania Bellone ◽  
Luca Zammataro ◽  
Peter E. Schwartz ◽  
Alessandro D. Santin

Sign in / Sign up

Export Citation Format

Share Document